Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 16, 2013, Pages 2281-2296

  Forst, Thomas ^a   Pfützner, Andreas ^b  

^a Profil   (Germany)

^b Institute for Clinical Research and Development   (Germany)

Author keywords

Glucagon like peptide 1 receptor agonist; Lixisenatide; Type 2 diabetes mellitus

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; INSULIN; LIRAGLUTIDE; LIXISENATIDE; MESSENGER RNA; METFORMIN; PARACETAMOL; PIOGLITAZONE; PLACEBO; SULFONYLUREA;

AREA UNDER THE CURVE; ARTICLE; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELDERLY CARE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART PROTECTION; HORMONE RELEASE; HUMAN; HYPOGLYCEMIA; IC 50; INJECTION SITE DERMATITIS; MAXIMUM PLASMA CONCENTRATION; METABOLIC REGULATION; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; RECEPTOR AFFINITY; STOMACH EMPTYING; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; PEPTIDES; RECEPTORS, GLUCAGON; TREATMENT OUTCOME;

EID: 84885631857     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.838559     Document Type: Article

References (96)

1. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12 (Pubitemid 30609442)
2. Morrish NJ, Wang SL, Stevens LK, et al. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001;44(Suppl 2):S14-21 (Pubitemid 32844108)
3. Cubbon R, Kahn M, Kearney MT. Secondary prevention of cardiovascular disease in type 2 diabetes and prediabetes: a cardiologist's perspective. Int J Clin Pract 2008;62:287-99
4. White JR. Economic considerations in treating patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2002;59(Suppl 9):S14-17
5. Shamseddeen H, Getty JZ, Hamdallah IN, Ali MR. Epidemiology and economic impact of obesity and type 2 diabetes. Surg Clin North Am 2011;91:1163-72, vii
6. Fergusson LD, Sattar N. Reducing cardiovascular disease risk in type 2 diabetes: is the focus on glycaemia warranted Diabetes Obes Metab 2012;15:387-91
7. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577-96
8. van Dieren S, Czernichow S, Chalmers J, et al. Weight changes and their predictors amongst 11 140 patients with type 2 diabetes in the ADVANCE trial. Diabetes Obes Metab 2012;14:464-9
9. Nauck MA, Vilsboll T, Gallwitz B, et al. Incretin-based therapies: viewpoints on the way to consensus. Diabetes Care 2009;32(Suppl 2):S223-31
10. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705 (Pubitemid 46048557)
11. Vilsboll T, Christensen M, Junker AE, et al. Effects of glucagon-like peptide- 1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012;344:d7771
12. Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 2011;124:S3-18
13. Tourrel C, Bailbe D, Meile MJ, et al. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 2001;50:1562-70 (Pubitemid 33639596)
14. Farilla L, Hui H, Bertolotto C, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002;143:4397-408 (Pubitemid 35239574)
15. Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide- 1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004;109:962-5 (Pubitemid 38282847)
16. Gutzwiller JP, Goke B, Drewe J, et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 1999;44:81-6 (Pubitemid 29143284)
17. Forst T, Michelson G, Ratter F, et al. Addition of liraglutide in patients with type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function. Diabet Med 2012;29:1115-18
18. Kodera R, Shikata K, Kataoka HU, et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 2011;54:965-78
19. Drucker DJ, Rosen CF. Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology. Diabetologia 2011;54:2741-4
20. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012;8:728-42
21. Ceriello A, Colagiuri S, Gerich J, Tuomilehto J; Guideline Development Group. Guideline for management of postmeal glucose. Nutr Metab Cardiovasc Dis 2008;18:S17-33
22. Schrot RJ. Targeting plasma glucose: preprandial versus postprandial. Clin Diabetes 2004;22:169-72
23. Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003;88:3082-9 (Pubitemid 36877476)
24. Eng J, Kleinman WA, Singh L, et al. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992;267:7402-5
25. Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000;43:1664-9 (Pubitemid 30304999)
26. Malone J, Trautmann M, Wilhelm K, et al. Exenatide once weekly for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2009;18:359-67
27. Barnett AH. Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes. Core Evid 2011;6:67-79
28. Thorkildsen C, Neve S, Larsen BD, et al. Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice. J Pharmacol Exp Ther 2003;307:490-6 (Pubitemid 37310661)
29. Werner U, Haschke G, Herling AW, Kramer W. Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul Pept 2010;164:58-64
30. Liu Y-H, Ruus P. Pharmacokinetics and safety of the GLP-1 agonist AVE0010 in patient with renal impairment. Ann Meet Am Diabetes Assoc 2009;69:abstract 557-P
31. Distiller L, Ruus PE. Pharmacokinetics and pharmacodynamics of GLP-1 agonist AVE0010 in type 2 diabetes patients. Ann Meet Am Diabetes Assoc 2008;68:abstract 520-P
32. Fonseca VA, Alvarado-Ruiz R, Raccah D, et al. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care 2012;35:1225-31
33. Ahren B, Dimas A, Miossec P, et al. Efficacy and safety of lixisenatide once daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care 2013;36:2543-50
34. Pinget M, Goldenberg R, Niemoeller E, et al. Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). Diabetes Obes Metab 2013; Epub ahead of print
35. Seino Y, Min KW, Niemoeller E, Takami A; Investigators EG-LAS. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal- L-Asia). Diabetes Obes Metab 2012;14:910-17
36. Riddle MC, Forst T, Aronson R, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Diabetes Care 2013;36:2497-503
37. Riddle MC, Aronson R, Home P, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care 2013;36:2489-96
38. Rosenstock J, Raccah D, Koranyi L, et al. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care 2013; Epub ahead of print
39. Kapitza C, Forst T, Coester HV, et al. Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. Diabetes Obes Metab 2013;15:642-9
40. Lorenz M, Pfeiffer C, Steinsträer A, et al. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes - Relationship to postprandial glycemia. Regul Pept 2013;185C:1-8
41. Bolli G, Munteanu M, Dotsenko S, et al. Efficacy and safety of lixisenatide once-daily versus placebo in patients with type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). Diabetic Medicine 2013; In press
42. Ratner R, Hanefeld M, Shamanna P, et al. Efficacy and safety of lixisenatide once daily versus placebo in patients with T2DM insufficiently controlled on sulfonylurea + metformin (GetGoal-S) [abstract 785]. Diabetologia 2011;54:1-542
43. Fukushima M, Suzuki H, Seino Y. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract 2004;66(Suppl 1):S37-43 (Pubitemid 39572582)
44. Yabe D, Kuroe A, Lee S, et al. Little enhancement of meal-induced glucagonlike peptide 1 secretion in Japanese: comparison of type 2 diabetes patients and healthy controls. J Diabetes Invest 2010;1:56-9
45. Raccah D, Miossec P, Esposito V, et al. Efficacy and safety of lixisenatide in elderly (65 yr) and very elderly (75 yr) patients with type 2 diabetes: an analysis from the GetGoal phase 3 program. Poster 972-P, presented at 72nd Scientific Sessions of the American Diabetes Association; 8 - 12 June 2012; Philadelphia, PA; 2012
46. Ban K, Noyan-Ashraf MH, Hoefer J, et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008;117:2340-50 (Pubitemid 351653542)
47. Gardiner SM, March JE, Kemp PA, et al. Possible involvement of GLP-1(9- 36) in the regional haemodynamic effects of GLP-1(7-36) in conscious rats. Br J Pharmacol 2010;161:92-102
48. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev 1999;20:876-913 (Pubitemid 30647076)
49. Tomas E, Habener JF. Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis. Trends Endocrinol Metab 2010;21:59-67
50. Sokos GG, Nikolaidis LA, Mankad S, et al. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006;12:694-9 (Pubitemid 44881367)
51. Bergenstal RM, Wysham C, Macconell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010;376:431-9
52. Courreges JP, Vilsboll T, Zdravkovic M, et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. Diabet Med 2008;25:1129-31
53. Huber J, Janecek E, Meister S, et al. Cardioprotective effect of the GLP-1 receptor agonist lixisenatide on ischemia-reperfusion-induced injury in the isolated rat heart. Diabetes 2011;60:abstract A265
54. Wohlfart P, Linz W, Linz D, et al. Cardioprotective effect of chronic treatment with lixisenatide in an in vivo rat model of myocardial ischaemia/reperfusion-induced injury. Presented at the 48th European Association for the Study of Diabetes Annual Meeting; 1 - 5 October 2012; Berlin, Germany; 2012
55. Robinson LE, Holt TA, Rees K, et al. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open 2013;3;e001986
56. Basu A, Charkoudian N, Schrage W, et al. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab 2007;293:E1289-95 (Pubitemid 350106596)
57. Golpon HA, Puechner A, Welte T, et al. Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat. Regul Pept 2001;102:81-6 (Pubitemid 33135568)
58. Richter G, Feddersen O, Wagner U, et al. GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery. Am J Physiol 1993;265:L374-81
59. Hattori Y, Jojima T, Tomizawa A, et al. A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia 2010;53:2256-63
60. Nystrom T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide- 1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004;287:E1209-15 (Pubitemid 39491964)
61. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47
62. Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008;24:275-86 (Pubitemid 351160260)
63. Mafong DD, Henry RR. The role of incretins in cardiovascular control. Curr Hypertens Rep 2009;11:18-22
64. Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-78
65. Okerson T, Yan P, Stonehouse A, Brodows R. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Am J Hypertens 2010;23:334-9
66. Gutzwiller JP, Tschopp S, Bock A, et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and ininsulin-resistant obese men. J Clin Endocrinol Metab 2004;89:3055-61 (Pubitemid 38766408)
67. Monami M, Cremasco F, Lamanna C, et al. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res 2011;2011:215764
68. ClinicalTrials Evaluation of cardiovascular outcomes in patients with type 2 diabetes after acute coronary syndrome during treatment with AVE0010 (Lixisenatide) (ELIXA) Available from: http://clinicaltrials.gov/show/ NCT01147250 [Accessed 28 February 2013]
69. Werner U, Gerlach M, Hofmann M, Herling AW. The GLP-1 receptor agonist AVE0010 abolishes OGTT-induced blood glucose excursion in healthy, normoglycemic dog without risk of hypoglycaemia [abstract 0486-P]. Poster presented at the 67th Scientific Session of the American Diabetes Association; 22 - 26 June 2007; Chicago, IL
70. Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes 2011;60:1561-5
71. Alssema M, Dekker JM, Nijpels G, et al. Proinsulin concentration is an independent predictor of all-cause and cardiovascular mortality: an 11-year follow-up of the Hoorn Study. Diabetes Care 2005;28:860-5 (Pubitemid 40434486)
72. Zethelius B, Lithell H, Hales CN, Berne C. Insulin sensitivity, proinsulin and insulin as predictors of coronary heart disease. A population-based 10-year, follow-up study in 70-year old men using the euglycaemic insulin clamp. Diabetologia 2005;48:862-7 (Pubitemid 40767978)
73. Oh JY, Barrett-Connor E, Wedick NM. Sex differences in the association between proinsulin and intact insulin with coronary heart disease in nondiabetic older adults: the Rancho Bernardo Study. Circulation 2002;105:1311-16 (Pubitemid 34260421)
74. Wiberg B, Sundstrom J, Zethelius B, Lind L. Insulin sensitivity measured by the euglycaemic insulin clamp and proinsulin levels as predictors of stroke in elderly men. Diabetologia 2009;52:90-6
75. Wohlin M, Sundstrom J, Arnlov J, et al. Impaired insulin sensitivity is an independent predictor of common carotid intima-media thickness in a population sample of elderly men. Atherosclerosis 2003;170:181-5 (Pubitemid 37083578)
76. Zethelius B, Byberg L, Hales CN, et al. Proinsulin is an independent predictor of coronary heart disease: report from a 27-year follow-up study. Circulation 2002;105:2153-8 (Pubitemid 34517158)
77. Forst T, Pfutzner A, Lubben G, et al. Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk-the PIOSTAT Study. Metabolism 2007;56:491-6 (Pubitemid 46437254)
78. Fritsche A, Madaus A, Stefan N, et al. Relationships among age, proinsulin conversion, and beta-cell function in nondiabetic humans. Diabetes 2002;51(Suppl 1):S234-9 (Pubitemid 34761521)
79. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100 (Pubitemid 40616618)
80. Vilsboll T, Brock B, Perrild H, et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus. Diabet Med 2008;25:152-6 (Pubitemid 351293400)
81. Del Prato S, Barnett AH, Huisman H, et al. Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 2011;13:258-67
82. Pratley RE, Schweizer A, Rosenstock J, et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naive patients: analysis of pooled vildagliptin monotherapy database. Diabetes Obes Metab 2008;10:931-8
83. Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006;49:2564-71
84. Forst T, Dworak M, Berndt-Zipfel C, et al. Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the b cell of patients with type 2 diabetes mellitus. Diabetes Obes Metab 2013;15:576-9
85. Tews D, Werner U, Eckel J. Enhanced protection against cytokine- and fatty acid-induced apoptosis in pancreatic beta cells by combined treatment with glucagon-like peptide-1 receptor agonists and insulin analogues. Horm Metab Res 2008;40:172-80 (Pubitemid 351690520)
86. Haschke G, Haag-Diergarten S, Werner U, et al. The GLP-1 receptor agonist AVE0010 preserves beta cell function and insulin secretion after a 6 week treatment in make obese Zucker diabetic fatty rats - an isolated perfusion pancreas study [abstract]. Diabetologia 2006;49:400-1
87. Becker RH, Kapitza C, Stechl J, et al. Restitution of glucose disposition with lixisenatide in healthy subjects and patients with type 2 diabetes [abstract 813]. Diabetologia 2012;55:S1-S538
88. Ratner RE, Hanefeld M, Shamanna P, et al. Post-meal pharmacodynamic profile of lixisenatide once daily vs placebo in T2DM insufficiently controlled on sulfonylureametformin (GetGoal-S) [abstract D-0743]. Poster presented at the International Diabetes Federation's 21st World Diabetes Congress; 5 - 8 December 2011; Dubai, United Arab Emirates; 2011
89. Gutniak M, Orskov C, Holst JJ, et al. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 1992;326:1316-22
90. Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7- 36 amide) in type 2 (non-insulindependent) diabetic patients. Diabetologia 1993;36:741-4 (Pubitemid 23218642)
91. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824-30 (Pubitemid 34233752)
92. Hui H, Nourparvar A, Zhao X, Perfetti R. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic5'-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 2003;144:1444-55 (Pubitemid 36432086)
93. Wang Y, Perfetti R, Greig NH, et al. Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. J Clin Invest 1997;99:2883-9 (Pubitemid 27278664)
94. Nauck MA, Heimesaat MM, Orskov C, et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993;91:301-7 (Pubitemid 23037285)
95. Quddusi S, Vahl TP, Hanson K, et al. Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans. Diabetes Care 2003;26:791-8 (Pubitemid 36929345)
96. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev 2012;33:187-215